Correlation Between Sonnet Biotherapeutics and Neurosense Therapeutics

Can any of the company-specific risk be diversified away by investing in both Sonnet Biotherapeutics and Neurosense Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sonnet Biotherapeutics and Neurosense Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Sonnet Biotherapeutics Holdings and Neurosense Therapeutics, you can compare the effects of market volatilities on Sonnet Biotherapeutics and Neurosense Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sonnet Biotherapeutics with a short position of Neurosense Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sonnet Biotherapeutics and Neurosense Therapeutics.

Diversification Opportunities for Sonnet Biotherapeutics and Neurosense Therapeutics

0.12

Correlation Coefficient

Sonnet Biotherapeutics  Neurosense Therapeutics

Average diversification

The 3 months correlation between Sonnet and Neurosense is 0.12. Overlapping area represents the amount of risk that can be diversified away by holding Sonnet Biotherapeutics Holding and Neurosense Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Neurosense Therapeutics and Sonnet Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sonnet Biotherapeutics Holdings are associated (or correlated) with Neurosense Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Neurosense Therapeutics has no effect on the direction of Sonnet Biotherapeutics i.e., Sonnet Biotherapeutics and Neurosense Therapeutics go up and down completely randomly.

Pair Corralation between Sonnet Biotherapeutics and Neurosense Therapeutics

Given the investment horizon of 90 days Sonnet Biotherapeutics Holdings is expected to under-perform the Neurosense Therapeutics. In addition to that, Sonnet Biotherapeutics is 1.13 times more volatile than Neurosense Therapeutics. It trades about -0.21 of its total potential returns per unit of risk. Neurosense Therapeutics is currently generating about 0.02 per unit of volatility. If you would invest  122.00  in Neurosense Therapeutics on October 8, 2024 and sell it today you would lose (3.00) from holding Neurosense Therapeutics or give up 2.46% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	98.41%
Values	Daily Returns

Sonnet Biotherapeutics Holding  vs.  Neurosense Therapeutics

Sonnet Biotherapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Sonnet Biotherapeutics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Neurosense Therapeutics

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Neurosense Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Neurosense Therapeutics may actually be approaching a critical reversion point that can send shares even higher in February 2025.

Pair Trading with Sonnet Biotherapeutics and Neurosense Therapeutics

The main advantage of trading using opposite Sonnet Biotherapeutics and Neurosense Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sonnet Biotherapeutics position performs unexpectedly, Neurosense Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurosense Therapeutics will offset losses from the drop in Neurosense Therapeutics' long position.

The idea behind Sonnet Biotherapeutics Holdings and Neurosense Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.